reports
- Hilde Van Boxstael
- Michiel Declercq
- Wim Lewi
- Guy Sips
- Jacob Mekhael
- Kristof Samoy
- Lynn Hautekeete
- Michiel Declercq
- Sharad Kumar S.P
- Thibault Leneeuw
- Thomas Couvreur
- Thomas Vranken
- Wim Hoste
- Wim Lewi
Dynamic Top Pick List Update October 2024 – Adding NN Group
We maintain a defensive stance on the market for 2H24. The long anticipated expectations for interest rate cuts by central banks will finally come to pass. The election fever in the US is reaching boiling point and the conversations are becoming more polarised than before. Also corporate profit growth in Europe slows and the French elections have cast a negative spell. In Germany by-elections in the Eastern part showed a shift to extreme right and left that will make budget decisions even more ...
BEKB BEKAERT SA
ABN ABN AMRO BANK NV DEPOSITARY RECEIPTS
FAGR FAGRON SA
EVS EVS BROADCAST EQUIPMENT SA
XIOR XIOR STUDENT HOUSING N.V.
SOLB SOLVAY SA
COFB COFINIMMO SA
DIE D'IETEREN SA
SOF SOFINA SA
IBAB ION BEAM APPLICATIONS SA
ACKB ACKERMANS & VAN HAAREN NV
KIN KINEPOLIS GROUP NV
NN NN GROUP N.V.
TINC TINC COMM. VA
FUR FUGRO NV
SYENS SYENSQO
IBA et l'Institut Jules Bordet piloteront le projet IHI Accelerate.EU ...
IBA et l'Institut Jules Bordet piloteront le projet IHI Accelerate.EU pour créer une chaîne de valeur complète pour l'Astate-211 Une initiative de 16 millions d'euros pour établir l'autonomie stratégique de l'UE en matière de thérapies alpha contre le cancer Louvain-la-Neuve, Belgique, 3 octobre 2024 - IBA (Ion Beam Applications S.A., EURONEXT), le leader mondial de la technologie d’accélération de particules et le premier fournisseur mondial de solutions de production de radiopharmaceutiques, annonce aujourd’hui que la Commission européenne a approuvé le financement du projet Accelerate.E...
IBA and Jules Bordet Institute to lead IHI project Accelerate.EU to cr...
IBA and Jules Bordet Institute to lead IHI project Accelerate.EU to create complete Astatine-211 value chain A EUR 16 million Initiative to Establish Strategic EU Autonomy in Alpha Therapies for Cancer Louvain-la-Neuve, Belgium, October 3, 2024 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of radiopharmaceutical production solutions, is pleased to announce that the European Commission has approved the financing of the Accelerate.EU project launching on October 1, 2024. IBA’s key role in this new project...
IBA - Regulated Information
IBA - Regulated Information (Article 14, paragraph 1 of the law of 2 May 2007 on the disclosure of major holdings) Louvain-la-Neuve, Belgium, October 1st, 2024 06:00 Summary of the notification IBA (Ion Beam Applications), the world’s leading provider of proton therapy solutions for the treatment of cancer, announces that it has to issue a transparency notification, in accordance with Article 14, al. 1 of the Transparency Law of May 2, 2007 on disclosure of major holdings, further to the notification received on September 26, 2024. In its notification, Vallcara Limited indicate...
IBA SA – NOTIFICATION TRANSPARENCE
IBA SA – NOTIFICATION TRANSPARENCE (article 14, alinéa 1er de la loi du 2 mai 2007 relative à la publicité des participations importantes) Louvain-la-Neuve, Belgique, le 1er octobre 2024, 18:00 Résumé de la notification IBA (Ion Beam Applications SA), le premier fournisseur mondial de solutions de protonthérapie pour le traitement du cancer, annonce devoir effectuer une notification en matière de transparence conformément à l'article 14, alinéa 1er de la loi du 2 mai 2007 relative à la publicité des participations importantes (« loi transparence »), à la suite d’une notificati...
- Hilde Van Boxstael
- Jacob Mekhael
- Michiel Declercq
- Wim Lewi
- Michiel Declercq
IBA Ready to Act (inium 225)
Earlier this week, IBA's joint venture PanTera secured € 93m in an oversubscribed Series A funding round, making it the largest in Belgian life science history. The post money valuation of € 280m implies a valuation of IBA's stake of € 88m or € 2.9ps, or comfortably above the previous book value of € 0.6ps. Incorporating this into our model, we increased our TP from € 16.0 to € 18.0 per share on Wednesday and reiterated our Buy rating. In this note, we take a closer look at the strong growth dri...
- ING Helpdesk
- Michiel Declercq
IBA Pantera gets € 280m valuation after largest Series A in Belgian LS...
This morning, IBA announced that Pantera secured € 93m in an oversubscribed series A round (the largest in Belgian life science history), valuing Pantera at € 280m post money valuation. Additionally, IBA and SFPIM will convert € 7.2m in convertible loans, while € 33.8m in debt has also been secured, bringing the total amount raised to € 134m. Following the transaction, IBA's will hold a 31.3% stake in Pantera, compared to 47.8% previously. The funds will be used primarily to support the construc...
- Guy Sips
- Michiel Declercq
- Sharad Kumar S.P
- Sharad Kumar S.P
Holdings Report - August 2024 KBCS Holdings Universe Up 0.5% Thanks To...
1M Performance - Absolute: During July'24 (1M period), the KBCS Holdings Universe posted a return of 0.5% which was mainly driven by multi-asset holdings (+1.7%) while single-asset holdings posted a negative return of -1.3%. The 3 top performers during the period were HAL Trust (+5.1%), Texaf (+2.9%), and The Infrastructure Company (TINC, +9.6%) while the 3 worst performers were Brederode (-2.8%), Solvac (-5.3%), and Whitestone Group (-7.2%). YTD Performance - Relative: On a YTD basis (as of A...
GBLB GROUPE BRUXELLES LAMBERT SA
HAL HAL TRUST
DIE D'IETEREN SA
SOF SOFINA SA
SOLV SOLVAC S.A.
GIMB GIMV NV
QFG QUEST FOR GROWTH
ACKB ACKERMANS & VAN HAAREN NV
TUB FINANCIERE DE TUBIZE S.A.
HEIO HEINEKEN HOLDING N.V.
KBCA KBC ANCORA SCA
TEXF TEXAF
BREB BREDERODE S.A.
TINC TINC COMM. VA
ROCK WHITESTONE GROUP
IBA’s joint venture PanTera secures EUR 93 million in oversubscribed S...
IBA’s joint venture PanTera secures EUR 93 million in oversubscribed Series A round to accelerate global actinium-225 production Louvain-la-Neuve, Belgium, September 11, 2024 – IBA (Ion Beam Applications S.A), the world leader in particle accelerator technology, is pleased to share the below press release from its joint venture PanTera, which is focussed on the production of actinium-225, a novel radioisotope used in a new class of targeted treatments for cancer. The Series A financing values PanTera at about EUR 280 million post money. Prior to the funding round, IBA had a 47.8% sharehold...
PanTera, la joint-venture d’IBA, obtient 93 millions d'euros lors d'un...
PanTera, la joint-venture d’IBA, obtient 93 millions d'euros lors d'une levée de fonds de série A sursouscrite pour accélérer la production mondiale d'actinium-225 Louvain-La-Neuve, Belgique, le 11 septembre 2024 - IBA (Ion Beam Applications S.A.), le leader mondial de la technologie d’accélération de particules, partage aujourd’hui le communiqué de presse ci-dessous concernant sa joint-venture PanTera qui a pour objectif d’assurer la production à grande échelle d'actinium-225, un radioisotope novateur utilisé dans une nouvelle classe de traitements ciblés contre le cancer. La levée de fon...
- Guy Sips
- Jacob Mekhael
- Kristof Samoy
- Lynn Hautekeete
- Michiel Declercq
- Sharad Kumar S.P
- Thibault Leneeuw
- Thomas Couvreur
- Thomas Vranken
- Wim Hoste
- Wim Lewi
Dynamic Top Pick List Update September 2024 –Cofinimmo & Kinepolis in;...
In this September update of our Dynamic Top Pick List we make 4 changes. •We include Cofinimmo in our Dynamic Top Pick List after our recent upgrade from Accumulate to Buy. We expect the name to outperform in a decreasing interest rate environment given its relatively high leverage and cheap valuation. We also believe the risk of a dilutive equity raise eased when the FY24 capex decreased from € 320m to € 250m. The management stays disciplined in its capex program and continues to focus on asse...
BEKB BEKAERT SA
ABN ABN AMRO BANK NV DEPOSITARY RECEIPTS
FAGR FAGRON SA
EVS EVS BROADCAST EQUIPMENT SA
XIOR XIOR STUDENT HOUSING N.V.
SOLB SOLVAY SA
COFB COFINIMMO SA
DIE D'IETEREN SA
SOF SOFINA SA
VAN VAN DE VELDE S.A.
IBAB ION BEAM APPLICATIONS SA
ACKB ACKERMANS & VAN HAAREN NV
CPINV CARE PROPERTY INVEST SA
KIN KINEPOLIS GROUP NV
TINC TINC COMM. VA
FUR FUGRO NV
SYENS SYENSQO
- MarketLine Department
EXOR S.p.A. - Mergers & Acquisitions (M&A), Partnerships & Alliances
Summary Marketline's EXOR S.p.A. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by EXOR S.p.A. - Mergers & Acquisitions (M&A), Partnerships & Alliances since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports off...
- ING Helpdesk
- Guy Sips
- Hilde Van Boxstael
- Kristof Samoy
- Michiel Declercq
- Wim Hoste
- Wim Lewi
IBA Reports Half Year 2024 Results
IBA Reports Half Year 2024 Results GROUP REVENUES UP 21.9% ACCELERATED BACKLOG CONVERSION IN PROTON THERAPY AND OTHER ACCELERATORS STRONG GROSS MARGIN IMPROVEMENT AND BREAKEVEN REBIT Louvain-la-Neuve, Belgium, 29 August 2024 - IBA (Ion Beam Applications S.A), the world leader in particle accelerator technology, today announces its consolidated results for the first half of 2024. (EUR 000)H1 2024H1 2023VarianceVariance %Total Revenues206 452169 41837 03421.9% Proton Therapy107 72495 08212 64213.3% Other Accelerators70 07841 35428 72469.5% Dosimetry28 64932 982-4 333-13...
IBA publie ses résultats du premier semestre 2024
IBA publie ses résultats du premier semestre 2024 REVENUS DU GROUPE EN HAUSSE DE 21,9% ACCELERATION DE LA CONVERSION DU CARNET DE COMMANDES EN PROTONTHÉRAPIE ET AUTRES ACCELERATEURS FORTE AMELIORATION DE LA MARGE BRUTE ET REBIT À L’EQUILIBRE Louvain-La-Neuve, Belgique, jeudi 29 août 2024 - IBA (Ion Beam Applications S.A.), le leader mondial de la technologie d’accélération de particules, annonce ce jour ses résultats consolidés pour le premier semestre 2024. (EUR 000)S1 2024S1 2023VariationVariation %Total Ventes et Prestations206 452169 41837 03421,9%Protonthérapie 107 72495 082...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.